SNPMiner Trials (Home Page)
Report for Clinical Trial NCT00626223
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
A randomized prospective study was done to determine whether i.v. 5-methyltetrahydrofolate vs
oral folate improved survival in ESRD patients. Homocysteine, CRP, Lp(a), albumin, folates,
vitamin B6 and B12 were checked. The 5-MTHF treated group was associated with lowered C
reactive protein and higher survival than the folate treated group.
2 Interventions
Name: 5-MTHF (5-methyltetrahydrofolate)
Description: 50 mg intravenous at the end of each hemodialysis session
Type: Drug
Name: folic acid
Description: 5 mg per day of oral folic acid
Type: Drug
Primary Outcomes
Measure: survival Time: 55 months
Secondary Outcomes
Measure: Risk factors for cardiovascular disease in ESRD patients Time: 55 months
Measure: Homocysteine levels after 6, 12, 24 and 55 months Time: 55 months
Measure: CRP levels after 6, 12, 24 and 55 months Time: 55 months
Measure: Gene polymorphisms analysis on C677T and A1298C loci and differences in polymorphisms distribution in both groups Time: basal
Measure: Differences at baseline between the groups concerning age, dialysis age, CRP, albumin, haemoglobin, Lp(a), homocysteine, folate, B6 and B12 baseline levels Time: basal
Purpose: Treatment
Allocation: Randomized
Parallel Assignment
There are 2 SNPs
SNPs
1 A1298C
Gene polymorphisms analysis on C677T and A1298C loci and differences in polymorphisms distribution in both groups. --- C677T --- --- A1298C ---
2 C677T
Gene polymorphisms analysis on C677T and A1298C loci and differences in polymorphisms distribution in both groups. --- C677T ---
HPO Nodes